References
- S. Noble and J. A. Balfour, Meloxicam, Drugs 51 (1996) 424-430; DOI: 10.2165/00003495-199651030-00007.
- N. M. Davies and N. M. Skjodt, Clinical pharmacokinetics of meloxicam: a cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug, Clin. Pharmacokinet. 36 (1999) 115-126; DOI: 2165/00003088-199936020-00003.
- B. J. Gates, T. T. Nguyen, S. M. Setter and N. M. Davies, Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety, Expert Opin. Pharmacother. 6 (2005) 2117-2140; DOI: 10.1517/14656566.6.12.2117.
- M. R. Prausnitz, S. Mitragotri and R. Langer, Current status and future potential of transdermal drug delivery, Nat. Rev. Drug Discov. 3 (2004) 115-124; DOI: 10.1038/nrd1304.
- E. Beetge, J. D. Plessis, D. G. Muller, C. Goosen and F. J. Van Rensburg, The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAIDs on their transdermal absorption, Int. J. Pharm. 193 (2000) 261-264; DOI: 10.1016/S0378-5173(99)00340-3.
- P. Stei, B Kruss, J. Weigleb and V. Trach, Local tissue tolerability of meloxicam, a new NSAID: indications for parenteral, dermal and mucosal administration, Br. J. Rheumatol. 35 (1996) 44-50; DOI: 10.1093/rheumatology/35.suppl_1.44.
- R. Jantharaprapap and G. Stagni, Effects of penetration enhancers on in vitro permeability of meloxicam gels, Int. J. Pharm. 343 (2007) 26-33; DOI: 10.1016/j.ijpharm.2007.04.011.
- J. S. Chang, Y. B. Huang, S. S. Hou, R. J. Wang, P. C. Wu and Y. H. Tsai, Formulation optimization of meloxicam sodium gel using response surface methodology, Int. J. Pharm. 338 (2007) 48-54; DOI: 10.1016/j.ijpharm.2007.01.033.
- Y. Yuan, S. M. Li, F. K. Mo and D. F. Zhong, Investigation of microemulsion system for transdermal delivery of meloxicam, Int. J. Pharm. 321 (2006) 117-123; DOI: 10.1016/j.ijpharm.2006.06.021.
- ICH Q2 (R1) Validation of Analytical Procedures: Text and Methodology, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva 2005, Switzerland.
- M. Joshi and V. Patravale, Nanostructured lipid carrier (NLC) based gel of celecoxib, Int. J. Pharm. 346 (2008) 124-132; DOI: 10.1016/j.ijpharm.2007.05.060.
- United States Pharmacopoeia 24, National Formulary 19, USP Pharmacopoeial Convention, Rockwille (MD) 2000.
- ICH Topic Q1 A (R2) Stability Testing of new Drug Substances and Products (2005), International Conference on Harmonisation of Technical requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland.
- B. J. Vermeer, Skin irritation and sensitization, J. Control. Rel. 15 (1991) 261-265; DOI: 10.1016/0168-3659(91)90117-V.
- E. Pontiki and D. Hadjipavlou-Litina, Synthesis of phenyl-substituted amides with antioxidant and anti-inflammatory activity as novel lipoxygenase inhibitors, Med. Chem. 3 (2007) 175-186; DOI: 10.2174/157340607780059512.
- M. D. Joshi and V. B. Patravale, Formulation and evaluation of nanostructured lipid carrier (NLC) based gel of valdecoxib, Drug Dev. Ind. Pharm. 32 (2006) 911-918; DOI: 10.1080/03639040600814676.
- R. Sanghavi, R. Narazaki, S. G. Machatha and S. H. Yalkowsky, Solubility improvement of drugs using N-methyl pyrrolidone, AAPS PharmSci Tech. 9 (2008) 366-376; DOI: 10.1208/s12249-008-9050-z.
- P. J. Lee, R. Langer and V. P. Shastri, Role of N-methyl pyrrolidone in the enhancement of aqueous phase transdermal transport, J. Pharm. Sci. 94 (2005) 912-917; DOI: 10.1002/jps.20291.
- A. C. Williams and B. W. Barry, Penetration enhancers, Adv. Drug Del. Rev. 56 (2004) 603-618; DOI:10.1016/j.addr.2003.10.025.